Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.62 |
| ▸ | HDAC4 | P56524 | 9/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13598312 | 0.96 | GPR119 (0.60) | GPR119HDAC4KDM4EMEN1ALDH1A1 | |
| SCHEMBL13598310 | 0.93 | GPR119 (0.62) | GPR119HDAC4HDAC6HDAC1 | |
| SCHEMBL4416116 | 0.93 | GPR119 (0.62) | GPR119HDAC4HDAC6HDAC1 | |
| SCHEMBL4420008 | 0.92 | GPR119 (0.61) | GPR119HDAC4HDAC6HDAC1 | |
| SCHEMBL4412793 | 0.92 | GPR119 (0.64) | GPR119HDAC4HDAC6HDAC1 | |
| SCHEMBL4427036 | 0.89 | GPR119 (0.67) | GPR119HDAC4HDAC6 | |
| SCHEMBL4420584 | 0.88 | GPR119 (0.69) | GPR119HDAC4KDM4EMEN1ALDH1A1 | |
| SCHEMBL13598309 | 0.87 | GPR119 (0.62) | GPR119HDAC4HDAC6HDAC1 | |
| SCHEMBL4419118 | 0.87 | GPR119 (0.68) | GPR119HDAC4HDAC6 | |
| SCHEMBL4414280 | 0.85 | GPR119 (0.46) | GPR119HDAC4KDM4EHPGDHDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325924-A1 | GPCR Agonists | PROSIDION LIMITED (GB) | 2009-12-31 | — | — | US | disclosed |
| US-20090325924-A1 | GPCR Agonists | PROSIDION LIMITED (GB) | 2009-12-31 | — | — | US | disclosed |
| US-20090325924-A1 | GPCR Agonists | PROSIDION LIMITED (GB) | 2009-12-31 | — | — | US | disclosed |
| WO-2007003960-A1 | GPCR AGONISTS | PROSIDION LIMITED (GB) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325924-A1 | GPCR Agonists | GPR119, GCGR, GPR27 | GPR119 1/4885HDAC4 2550/4885KDM4E 3925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.